11results about How to "Strong immune response" patented technology

This invention belongs to the field of immunology and relates to a single-domain antibody against TSLP and its uses. The single-domain antibody is composed of heavy chains, including heavy chain CDR1 shown in any one of SEQ ID NO:42-SEQ ID NO:48 or SEQ ID NO:73, heavy chain CDR2 shown in any one of SEQ ID NO:49-SEQ ID NO:50, and heavy chain CDR3 shown in any one of SEQ ID NO:51-SEQ ID NO:61 or SEQ ID NO:74-SEQ ID NO:75. Compared with the prior art, the beneficial effects of this invention are: this invention uses bioengineering technology to screen for single-domain antibodies specifically targeting TSLP, and the antibody affinity is good.

The application discloses a porcine rotavirus VP7 protein conserved dominant B cell antigen epitope peptide or a combination thereof or a nucleic acid molecule and application, and further discloses a porcine rotavirus VP7 protein polyepitope fusion protein and a preparation method and application thereof.The polyepitope fusion protein can not only induce high-level specific antibody response and cellular immune response to the VP7 protein, effectively inhibit porcine rotavirus infection, but also has high safety and stability.Compared with a traditional fusion protein, the polyepitope fusion protein has significant advantages in production cost and immunization efficacy, and provides a feasible porcine rotavirus prevention and control scheme for the pig industry.

An anti-MASP2 antibody, an antigen-binding fragment thereof and the medical use thereof. Specifically, provided are an anti-MASP2 antibody or an antigen-binding fragment thereof, a pharmaceutical composition thereof, a method for treating diseases such as IgA nephropathy and a related pharmaceutical use.

The application belongs to the field of immunology and relates to an anti-LAG3 single-domain antibody and use thereof.The single-domain antibody is composed of a heavy chain, the heavy chain comprising heavy chain CDR1 shown in any one of SEQ ID NO:22-SEQ ID NO:26, heavy chain CDR2 shown in any one of SEQ ID NO:27-SEQ ID NO:29, and heavy chain CDR3 shown in any one of SEQ ID NO:30-SEQ ID NO:34.The beneficial effect of the application relative to the prior art is that the application uses biological genetic engineering technology to screen out a single-domain antibody specific to LAG3, and the antibody has good affinity.

The application belongs to the field of immunology and relates to a single-domain antibody against IL-17A and use thereof.The single-domain antibody is composed of a heavy chain, and the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2 and a heavy chain CDR3.The amino acid sequences of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 are one of (2)-(4) or (6)-(8).Compared with the prior art, the application has the beneficial effect that the single-domain antibody specific to IL-17A is screened by using biological genetic engineering technology, the antibody has good affinity, can block the release of cytokines by specific cells, has good binding activity through prokaryotic expression and eukaryotic expression, and has certain drugability.

The application provides an active polypeptide and application in prevention and / or treatment of HPV, and belongs to the technical field of biological medicine. The application provides a polypeptide with prevention and / or treatment activity, and the sequence of the polypeptide comprises SEQ ID No. 1. The polypeptide can directly serve as a medicine to effectively activate immunity, inhibit and eliminate human papilloma virus. The polypeptide can be used for injection alone as a medicine. The polypeptide can also induce single nucleated cells (PBMC) in vitro, culture CTL cells with specific killing of HPV, and through reinfusion of the CTL cells into a patient, directly kill tumors or stimulate immune response of the body, effectively kill HPV, make HPV in the patient turn from positive to negative, and finally achieve the effect of treatment. The polypeptide can also serve as a medicine for prevention of HPV, effectively stimulate strong immune response, and make the body produce a large number of immune cells to achieve the effect of protection and prevention.

Provided are an anti-CD40 antibody, an antigen-binding fragment and a medical use thereof, as well as a pharmaceutical composition containing the anti-CD40 antibody or antigen-binding fragment thereof, and a method for treating and preventing disease, in particular a method for treating autoimmune disease.

The present invention discloses an antigen delivery carrier that targets dendritic cells, promotes antigen lysosomal escape, and activates the immune system, and its preparation method and application. The present invention provides a carrier for delivering antigens into the body, which is a metal skeleton complex obtained by functionally modifying a metal skeleton material with polyethyleneimine and mannose. The antigen delivery carrier provided by the present invention has uniform particle size, good dispersibility, high biosafety, and a large antigen loading capacity. It exhibits high targeting to dendritic cells, increases the uptake of antigens by dendritic cells, promotes the maturation of dendritic cells, and promotes the cross-presentation of antigens in dendritic cells, and can efficiently activate CD4 + and CD8 + T cells, causing a strong immune response and killing cancer cells. This carrier has a wide range of applications and can be used to encapsulate single or multiple antigens, and has the ability to kill common tumors.

The invention relates to a dendrimer-based polypeptide nano vaccine as well as a preparation method and application thereof. The polypeptide nano vaccine is obtained by loading MnO2 nano particles on a functionalized dendrimer and wrapping a polypeptide antigen. After the polypeptide nano vaccine disclosed by the invention is injected into a mouse body through peritumoral injection, MnO2 plays a chemical kinetic treatment role through a Fenton-like reaction, and tumor cells are induced to generate immunogenic cell death, so that dendritic cell maturation is promoted; meanwhile, the polypeptide nano vaccine can activate an immune system and initiate potent immune response by activating a cGAS-STING pathway and being cooperated and combined with presentation of a polypeptide antigen OVA257-264, a new chemical kinetics / immune combined treatment strategy is provided, and the polypeptide nano vaccine has a remarkable inhibition effect on tumor growth and recurrence and has potential application value in the field of biological medicine.

This invention relates to a type I / II photodynamic carbon dot sensitized by D-π-A and encapsulated in an M1 macrophage membrane, its preparation method, and its application. The type I / II photodynamic carbon dot sensitized by D-π-A and encapsulated in an M1 macrophage membrane consists of an M1 macrophage membrane and carbon dots with a D-π-A configuration. The M1 macrophage membrane further encapsulates carbon dots with a D-π-A configuration. Compared with existing technologies, this invention is the first to design near-infrared excited D-π-A sensitizing carbon dots, which can be used as type I / II photosensitizers for hypoxia-modulated photodynamic immunotherapy.